Tag: Lung Cancer

NCT#:	NCT04929041
NCT QR Code
Title:	A082002 – Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
Protocol:	A082002
Cancer Type:	Lung Cancer
Study Sponsor:	Alliance/NCI
Brief Summary:	This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) vs. usual treatment alone in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Stereotactic body radiation therapy (SBRT) is a type of radiation therapy that uses high energy x-rays to kill tumor cells and shrink tumors. This method uses special equipment to position a patient and precisely deliver radiation to tumors with fewer doses over a shorter period and may cause less damage to normal tissue than conventional radiation therapy. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab and pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin, pemetrexed, paclitaxel and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.
Study Type:	Interventional
Date Opened at SVH:	April 14, 2022
Recruitment Status:	Recruiting
Study Population:
Eligibility Criteria:	See Schema
Principal Investigator:	Hong Zhao, MD, Oncology, Salinas Valley Health Cancer Care, (831) 755-1701
Participating Institution:	Salinas Valley Health
SVH Clinical Research Program:	Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager,  [email protected]
Link to ClinicalTrials.gov:	https://clinicaltrials.gov/ct2/show/record/NCT04929041?term=a082002&draw=2&rank=1
Schema	Schema

NCT#:	NCT04181060
NCT QR Code
Title:	Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Protocol:	EA5182
Cancer Type:	Lung
Study Sponsor:	NCI / ECOG-ACRIN
Brief Summary:	This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Study Type:	Interventional
Date Opened at SVH:	2-Sep-2021
Recruitment Status:	Recruiting
Study Population:
Eligibility Criteria:	See SCHEMA
Principal Investigator:	Hong Zhao, MD, Oncology, SVMC Cancer Care, (831) 755-1701
Participating Institution:	Salinas Valley Memorial Healthcare System & Salinas Valley Medical Clinics & Salinas Valley Memorial Hospital
SVH Clinical Research Program:	Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager,  [email protected]
Link to ClinicalTrials.gov:	https://clinicaltrials.gov/ct2/show/record/NCT04181060?term=EA5182&draw=2&rank=1
Physician Fact Sheet:	EA5182 SCHEMA